From a clinical and translational perspective, a combination of propionate and cisplatin may have better therapeutic effects on HCC than conventional treatment, so the selective GPR41 agonist may be a candidate as an adjuvant therapeutic agent for HCC [174]. This evidence concerns the gene FFAR3 and hepatocellular carcinoma.